公开(公告)号：US11970484B2

公开(公告)日：2024-04-30

申请号：US18166831

申请日：2023-02-09

Applicant: OrsoBio, Inc.

Inventor： Christian Gege ,  Olaf Kinzel ,  Eva Hambruch ,  Manfred Birkel ,  Claus Kremoser ,  Ulrich Deuschle

IPC: C07D409/14 ,  A61P1/16 ,  C07D209/18 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04

CPC classification number: C07D409/14 ,  A61P1/16 ,  C07D209/18 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04 ,  C07B2200/05

Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRα and/or LXKβ) and act preferably as inverse agonists of LXR.

公开(公告)号：US11945801B2

公开(公告)日：2024-04-02

申请号：US17311121

申请日：2019-12-09

Applicant: Heptares Therapeutics Limited

Inventor： Giles Albert Brown ,  Barry John Teobald ,  Benjamin Gerald Tehan

IPC: C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D451/02 ,  C07D451/04 ,  C07D451/14

CPC classification number: C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D451/02 ,  C07D451/04 ,  C07D451/14

Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; R1 and R4 are as defined herein.

公开(公告)号：US20230357214A1

公开(公告)日：2023-11-09

申请号：US18166831

申请日：2023-02-09

Applicant: OrsoBio, Inc.

Inventor： Christian GEGE ,  Olaf KINZEL ,  Eva HAMBRUCH ,  Manfred BIRKEL ,  Claus KREMOSER ,  Ulrich DEUSCHLE

IPC: C07D409/14 ,  A61P1/16 ,  C07D209/18 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04

CPC classification number: C07D409/14 ,  A61P1/16 ,  C07D209/18 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04 ,  C07B2200/05

Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRα and/or LXKβ) and act preferably as inverse agonists of LXR.

公开(公告)号：US11584765B2

公开(公告)日：2023-02-21

申请号：US16885604

申请日：2020-05-28

Applicant: Ecstasy LLC

Inventor： Xiaodong Wang ,  Hua Zhong

IPC: C07D205/04 ,  C07D409/04 ,  C07D211/12 ,  C07D211/34 ,  C07D223/04 ,  C07D223/06 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07F5/02 ,  C07D475/00 ,  C07D211/14 ,  C07D207/09 ,  C07D417/06 ,  C07D417/10 ,  C07D409/06 ,  C07D451/02 ,  C07D473/00 ,  C07D471/08 ,  C07D513/04

Abstract: The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

公开(公告)号：US20230047296A1

公开(公告)日：2023-02-16

申请号：US17495115

申请日：2021-10-06

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  ASTEX THERAPEUTICS LIMITED

Inventor： Jeffrey K. KERNS ,  James Callahan ,  Hongxing Yan ,  Thomas Daniel Heightman ,  Charlotte Mary Griffiths-Jones ,  Alison Jo-Anne Woolford ,  Tindy Li ,  Ami Lakdawala Shah ,  Roderick S. Davis ,  David Norton ,  Jeffrey Charles Boehm ,  Paris L. Hamilton ,  Nicole Cathleen Goodwin ,  Yun Jin

IPC: C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D267/14 ,  C07D249/18 ,  C07D233/60 ,  C07D487/08 ,  C07D451/02 ,  A61P9/00 ,  A61P25/00 ,  A61P11/00 ,  A61P27/00 ,  A61P35/00 ,  A61P37/00 ,  C07D233/64 ,  C07D255/04 ,  C07D273/01 ,  C07D405/10

Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

公开(公告)号：US20230027362A1

公开(公告)日：2023-01-26

申请号：US17771773

申请日：2020-10-29

Applicant: DIGMBIO. INC.

Inventor： Eunhee Kim ,  Changmin Park ,  Sehwan Oh ,  Younghoon Kim ,  Juhee Lee ,  Jaehee Seol ,  Ahram Shim ,  Younggwan Kim ,  Tae-Sung Koo ,  Ki-Hong Jang

IPC: C07D217/24 ,  C07D401/12 ,  C07D451/02 ,  C07D417/12 ,  C07D401/06 ,  C07D401/14 ,  C07D405/12 ,  A61P27/02 ,  A23L33/00 ,  A23L33/10

Abstract: The present invention relates to isoquinolinone derivatives, a method for preparing the same, and a pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1 (PARP-1)-related diseases containing the same as an active ingredient. The isoquinolinone derivatives exhibit an excellent PARP-1 inhibitory effect at a concentration of nanomolar units, and further exhibit an excellent cytoprotective effect (apoptosis inhibitory effect) on ophthalmic diseases or disorders, specifically retinal disorders, and thus can be effectively used as a pharmaceutical composition for preventing or treating PARP-1-related diseases, for example, ophthalmic diseases or disorders, which contains the same as an active ingredient.

公开(公告)号：US20230026611A1

公开(公告)日：2023-01-26

申请号：US17766832

申请日：2020-10-06

Applicant: D. E. Shaw Research, LLC

Inventor： Fabrizio GIORDANETTO ,  Morten Østergaard JENSEN ,  Vishwanath JOGINI ,  Roger John SNOW

IPC: C07D211/34 ,  C07D211/22 ,  C07D295/096 ,  C07D211/56 ,  C07D205/04 ,  C07D243/08 ,  C07D211/52 ,  C07D451/02 ,  C07D207/08 ,  C07D223/04 ,  C07D211/28 ,  C07D211/26 ,  C07D211/32 ,  C07D241/04 ,  C07D211/60 ,  C07D211/70 ,  C07D211/58 ,  C07D211/42 ,  C07D401/04 ,  C07D401/06 ,  C07D471/10 ,  C07D401/12 ,  C07D413/04 ,  C07D405/12 ,  C07D403/12

Abstract: A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

公开(公告)号：US20230022157A1

公开(公告)日：2023-01-26

申请号：US17267362

申请日：2019-08-20

Applicant: Achillion Pharmaceuticals, Inc.

Inventor： Jason Allan Wiles ,  Venkat Rao Gadhachanda ,  Kyle J. Eastman ,  Godwin Pais

IPC: C07D403/14 ,  C07D401/14 ,  C07D491/052 ,  C07D471/04 ,  C07D487/04 ,  C07D451/02 ,  C07D405/14 ,  C07D409/14 ,  C07D519/00

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.

公开(公告)号：US20220402901A1

公开(公告)日：2022-12-22

申请号：US17760873

申请日：2020-09-17

Applicant: Bial - R&D Investments, S.A. ,  Fondazione Istituto Italiano di Tecnologia

Inventor： Renato T. Skerlj ,  Rita Scarpelli ,  Vincenzo Cilibrasi ,  Samantha Caputo

IPC: C07D413/04 ,  C07D451/02 ,  C07D491/107 ,  C07D487/04 ,  C07D471/10

Abstract: The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

公开(公告)号：US11465980B2

公开(公告)日：2022-10-11

申请号：US16286700

申请日：2019-02-27

Applicant: Trevena, Inc.

Inventor： Aimee Crombie Speerschneider ,  Dennis Shinji Yamashita ,  Philip Michael Pitis ,  Michael John Hawkins ,  Guodong Liu ,  Tamara Ann Miskowski Daubert ,  Catherine C. K. Yuan ,  Robert Borbo Kargbo ,  Robert Jason Herr ,  Donna Romero ,  Gregory J. Pacofsky

IPC: C07D401/12 ,  A61K31/445 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D241/04 ,  C07D451/02 ,  C07D211/22

Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.